From: Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer
Response Status
Survival
(month)
Serum sTRAIL Level (ng/ml)
Alive (n = 7)
20,6 ± 0,5
1,38 ± 0,10
Dead (n = 9)
9,4 ± 0,9
0,92 ± 0,05
Statistical analysis (unpaired
t-test)
p < 0,05 (p = 0,0001)
p < 0,05 (p = 0,0002)